Tianjin Medical University General Hospital
天津医科大学总医院
Listed for 30 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
Official links opened and checked on 2026-11-08.
Research at Tianjin Medical University General Hospital
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
- Nasopharyngeal carcinoma鼻咽癌1 paper led
- Oesophageal squamous cell carcinoma食管鳞状细胞癌5 papers led
- Hepatocellular carcinoma肝细胞癌22 papers led
- Stomach cancer胃癌30 papers led
- Hepatoblastoma肝母细胞瘤1 paper led
- Retinoblastoma视网膜母细胞瘤1 paper led
- Osteosarcoma骨肉瘤3 papers led
- Gastrointestinal stromal tumour胃肠道间质瘤2 papers led
- Neuroblastoma神经母细胞瘤0 papers led
- Multiple myeloma多发性骨髓瘤27 papers led1 open trial led
- B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病0 papers led1 open trial led
- Aplastic anaemia再生障碍性贫血23 papers led
- Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜1 paper led
- Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病22 papers led2 open trials led
- IgG4-related diseaseIgG4相关性疾病3 papers led
- Myasthenia gravis重症肌无力21 papers led1 open trial led
- Moyamoya disease烟雾病2 papers led
- Takayasu arteritis大动脉炎0 papers led
- Idiopathic pulmonary fibrosis特发性肺纤维化7 papers led
- Amyotrophic lateral sclerosis肌萎缩侧索硬化症1 paper led
- Spinal muscular atrophy脊髓性肌萎缩症1 paper led
- Duchenne muscular dystrophy杜氏肌营养不良2 papers led
- Alport syndromeAlport 综合征1 paper led
- IgA nephropathyIgA 肾病10 papers led
- Osteogenesis imperfecta成骨不全症4 papers led
- Primary biliary cholangitis原发性胆汁性胆管炎7 papers led
- Primary sclerosing cholangitis原发性硬化性胆管炎1 paper led
- Hirschsprung disease先天性巨结肠0 papers led
- Familial adenomatous polyposis家族性腺瘤性息肉病0 papers led
- Leber hereditary optic neuropathyLeber 遗传性视神经病变3 papers led
Not listed for: Chordoma, Ewing sarcoma, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Fanconi anaemia, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Fabry disease, Pompe disease, Behçet disease, Gaucher disease, Niemann–Pick disease type C, Congenital diaphragmatic hernia, Inherited epidermolysis bullosa, Hereditary angioedema, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.
Cancer
Nasopharyngeal carcinoma
鼻咽癌Led 1 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.04%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
2 hospitals in Tianjin for nasopharyngeal carcinoma183 hospitals in China for nasopharyngeal carcinoma
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
- Phase
- Phase 2
- Started
- 2024-01
- Registry
- NCT05956587
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChongqing, Fuzhou, Guangzhou, Hangzhou, Linyi, Liuzhou, Nanchang, Tianjin, Wuhan, Xi'an, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led1
All its trials on ClinicalTrials.gov, any status1
More papers found outside PubMed (not counted)1
Cancer
Oesophageal squamous cell carcinoma
食管鳞状细胞癌Led 5 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Tianjin for oesophageal squamous cell carcinoma192 hospitals in China for oesophageal squamous cell carcinoma
No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led5
- Innovative role of the antidepressant imipramine in esophageal squamous cell carcinoma treatment: Promoting apoptosis and protective autophagy.
- Single-cell sequencing analysis reveals cancer-associated pericyte subgroup in esophageal squamous cell carcinoma to predict prognosis.
- Early-onset esophageal squamous cell carcinoma with achalasia: A case report.
- Transgelin promotes ferroptosis to inhibit the malignant progression of esophageal squamous cell carcinoma.
- Mig-6 could inhibit cell proliferation and induce apoptosis in esophageal squamous cell carcinoma.
Chinese-language papers (not in the count)1
All its trials on ClinicalTrials.gov, any status2
More papers found outside PubMed (not counted)12
- 305P Safety and efficacy of endoscopic resection followed by adjuvant chemoradiotherapy (ERACT) for organ preservation in early-stage oesophageal squamous cell carcinoma with high-risk features: A prospective, multicenter, phase II clinical
- 1426P BL-B01D1, an EGFR x her3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC)
- Additional file 10 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop
- Additional file 11 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop
- Additional file 12 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop
- Additional file 13 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop
- Additional file 14 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop
- Additional file 15 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop
- Additional file 9 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop
- RETRACTED ARTICLE: Tumor-associated fibroblasts derived exosomes induce the proliferation and cisplatin resistance in esophageal squamous cell carcinoma cells through RIG-I/IFN-β signaling
- 166TiP Pembrolizumab combined with neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy followed surgery for locally advanced esophageal squamous cell carcinoma: Protocol for a multi-center, prospective, randomized-controlled, phas
- A Novel Potential Diagnostic and Prognostic Biomarker for Esophageal Cancer
Cancer
Hepatocellular carcinoma
肝细胞癌Led 22 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Tianjin for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma
No open trial on hepatocellular carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Over half of these papers are lab or animal studies.
Papers it led22
- DNASE1L3 regulates macrophage polarization through the NLRP3-GSDMD signaling pathway affecting hepatocellular carcinoma progression.
- Biomimetic Nanoparticles with Dual Targeting for Hepatocellular Carcinoma Promote Tumor Immune System Activation by Enhancing Extracellular ATP Homeostasis.
- LI-RADS for diagnosing hepatocellular carcinoma by contrast-enhanced US with SonoVue and Sonazoid-a single center prospective study.
- Retrospective Analysis of Aberrant Hepatic Artery in 1250 Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.
- Identification of a vascular invasion-related signature based on lncRNA pairs for predicting prognosis in hepatocellular carcinoma.
- Overexpression of NDRG1 leads to poor prognosis in hepatocellular carcinoma through mediating immune infiltration and EMT.
- Identification of SPP1 + macrophages as an immune suppressor in hepatocellular carcinoma using single-cell and bulk transcriptomics.
- Luteolin exerts anti-tumour immunity in hepatocellular carcinoma by accelerating CD8+ T lymphocyte infiltration.
- Nrf2/ASPM axis regulated vasculogenic mimicry formation in hepatocellular carcinoma under hypoxia.
- LOXL2 serves as a prognostic biomarker for hepatocellular carcinoma by mediating immune infiltration and vasculogenic mimicry.
- Interleukin-35 expression promotes hepatocellular carcinogenesis by inducing γδ T-cell exhaustion.
- Four-Pyroptosis Gene-Based Nomogram as a Novel Strategy for Predicting the Effect of Immunotherapy in Hepatocellular Carcinoma.
- Deoxyribonuclease 1-like 3 Inhibits Hepatocellular Carcinoma Progression by Inducing Apoptosis and Reprogramming Glucose Metabolism.
- LncRNA n339260 functions in hepatocellular carcinoma progression via regulation of miRNA30e-5p/TP53INP1 expression.
- γδ T cells: The potential role in liver disease and implications for cancer immunotherapy.
- Elevated expression of the MYB proto-oncogene like 2 (MYBL2)-encoding gene as a prognostic and predictive biomarker in human cancers.
- DNASE1L3 arrests tumor angiogenesis by impairing the senescence-associated secretory phenotype in response to stress.
- The role of different PI3K protein subtypes in the metastasis, angiogenesis and clinical prognosis of hepatocellular carcinoma.
- Long noncoding RNA TP53TG1 suppresses the growth and metastasis of hepatocellular carcinoma by regulating the PRDX4/β-catenin pathway.
- Pan-cancer analysis indicates that MYBL2 is associated with the prognosis and immunotherapy of multiple cancers as an oncogene.
- CircANKRD52 Promotes the Tumorigenesis of Hepatocellular Carcinoma by Sponging miR-497-5p and Upregulating BIRC5 Expression.
- Interleukin-35 has a tumor-promoting role in hepatocellular carcinoma.
Cancer
Stomach cancer
胃癌Led 30 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
3 hospitals in Tianjin for stomach cancer211 hospitals in China for stomach cancer
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
- Phase
- Phase 3
- Started
- 2025-05
- Registry
- NCT06901531
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Shanghai, Shijiazhuang, Tianjin, Wuhan, Xining, Zhengzhou
- RecruitingA Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor
- Phase
- Phase 1
- Started
- 2022-02
- Registry
- NCT05262491
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Chengdu, Hangzhou, Jinan, Nanchang, Tianjin
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led30
- CircFoxo3 knockdown inhibit gastric cancer progression by regulating Foxo3.
- In Silico Identification and Verification of the Anticancer Mechanism of TMBM-010 from Oxytropis herba with a Rational Delivery System Design.
- Identification of prognostic indicators for early recurrence of gastric cancer following laparoscopic gastrectomy.
- Tumor-Derived EBI3 Promotes CD8+ T-cell Exhaustion via STAT4-IL10/CCL5 in Gastric Cancer.
- Targeting Tumor Differentiation Grade-related Genes Prognostic Signature Including COL5A1 Based on Single-cell RNA-seq in Gastric Cancer.
- Potential Role of EBI3 in Gastric Cancer and Its Inductive Effects on T-Cell Exhaustion.
- Efficacy analysis of modified double band ligation-assisted endoscopic submucosal resection and endoscopic mucosal dissection in the treatment of gastric gastrointestinal stromal tumors (≤ 1.5 cm).
- RGS4 promotes the progression of gastric cancer through the focal adhesion kinase/phosphatidyl-inositol-3-kinase/protein kinase B pathway and epithelial-mesenchymal transition.
- Prognostic significance of lymphovascular invasion in pN0 stage gastric cancer: a propensity score matching analysis.
- A competing-risk nomogram for predicting gastric cancer-specific survival in patients over 70 years: A SEER-based study.
- Comparison of SOX and CAPOX in patients with advanced gastric cancer after laparoscopic D2 gastrectomy: A randomized controlled trial.
- Construction of store-operated calcium entry-related gene signature for predicting prognosis and indicates immune microenvironment infiltration in stomach adenocarcinomas.
- Different Methods of Minimally Invasive Esophagojejunostomy After Total Gastrectomy for Gastric Cancer: Outcomes from Two Experienced Centers.
- Relationship between histone demethylase LSD family and development and prognosis of gastric cancer.
- Prognostic value and immunological roles of GPX3 in gastric cancer.
- Efficacy of endoscopic ultrasound and endoscopic resection for esophageal schwannoma.
- SMPDL3B contributes to gastric adenocarcinoma cells progression by promoting the infiltration of M2 macrophages.
- Genetic mutation and tumor microbiota determine heterogenicity of tumor immune signature: Evidence from gastric and colorectal synchronous cancers.
- Comprehensive analysis to identify pseudogenes/lncRNAs-hsa-miR-200b-3p-COL5A2 network as a prognostic biomarker in gastric cancer.
- CD40×HER2 bispecific antibody overcomes the CCL2-induced trastuzumab resistance in HER2-positive gastric cancer.
- Temporal heterogeneity of HER2 expression in metastatic gastric cancer: a case report.
- Impact of Neoadjuvant Therapy on Minimally Invasive Surgical Outcomes in Advanced Gastric Cancer: An International Propensity Score-Matched Study.
- A novel ferroptosis-related lncRNA signature for prognosis prediction in gastric cancer.
- Construction and Validation of a Nomogram for the Preoperative Prediction of Lymph Node Metastasis in Gastric Cancer.
- RAI14 Regulated by circNFATC3/miR-23b-3p axis Facilitates Cell Growth and Invasion in Gastric Cancer.
- A comprehensive update on early gastric cancer: defining terms, etiology, and alarming risk factors.
- The Potential Role of REG Family Proteins in Inflammatory and Inflammation-Associated Diseases of the Gastrointestinal Tract.
- Cronkhite-Canada syndrome: An investigation in clinical features and pathogenesis.
- Ectopic insulinoma diagnosed by 68Ga-Exendin-4 PET/CT: A case report and review of literature.
- Primary hepatic squamous carcinoma concurrent with gastric signet ring cell carcinoma demonstrated by 18F-fluorodeoxyglucose positron emission tomography/computed tomography.
All its trials on ClinicalTrials.gov, any status9
- A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
- A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor
- A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
- A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment
- A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer Diagnosis
- HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer
- Study of Faecal Bacteria Detection in Early Screening and Diagnosis of GC
- Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)
- A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer
Cancer
Hepatoblastoma
肝母细胞瘤Led 1 of the 154 English-language PubMed papers on hepatoblastoma with an author in mainland China, 2021–2025: 0.7%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Tianjin for hepatoblastoma86 hospitals in China for hepatoblastoma
No open trial on hepatoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Cancer
Retinoblastoma
视网膜母细胞瘤Led 1 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 0.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Tianjin for retinoblastoma176 hospitals in China for retinoblastoma
No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Cancer
Osteosarcoma
骨肉瘤Led 3 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
13 hospitals in Tianjin for osteosarcoma570 hospitals in China for osteosarcoma
No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led3
- LAP2α orchestrates alternative lengthening of telomeres suppression through telomeric heterochromatin regulation with HDAC1: unveiling a potential therapeutic target.
- Identification and characterization of aging/senescence-induced genes in osteosarcoma and predicting clinical prognosis.
- Primary extraskeletal osteosarcoma of sigmoid mesocolon: a case report and a review of the literature.
Earlier papers (2016–2020)5
- By targeting TRAF6, miR-140-3p inhibits TGF-β1-induced human osteosarcoma epithelial-to-mesenchymal transition, migration, and invasion.
- Osteomalacia, renal Fanconi syndrome, and bone tumor.
- MicroRNA-375 as a potential serum biomarker for the diagnosis, prognosis, and chemosensitivity prediction of osteosarcoma.
- Exploring the key genes and pathways of osteosarcoma with pulmonary metastasis using a gene expression microarray.
- Long non-coding RNA small nucleolar RNA host gene 12 (SNHG12) promotes cell proliferation and migration by upregulating angiomotin gene expression in human osteosarcoma cells.
Cancer
Gastrointestinal stromal tumour
胃肠道间质瘤Led 2 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
6 hospitals in Tianjin for gastrointestinal stromal tumour240 hospitals in China for gastrointestinal stromal tumour
No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led2
- Efficacy analysis of modified double band ligation-assisted endoscopic submucosal resection and endoscopic mucosal dissection in the treatment of gastric gastrointestinal stromal tumors (≤ 1.5 cm).
- Differentiating Gastrointestinal Stromal Tumors From Leiomyomas of Upper Digestive Tract Using Convolutional Neural Network Model by Endoscopic Ultrasonography.
Earlier papers (2016–2020)5
- Treatment recommendations for small gastric gastrointestinal stromal tumors: positive endoscopic resection.
- Gastric carcinoma with a gastrointestinal stromal tumor - A case report and literature review.
- Ligation-Assisted Endoscopic Enucleation for the Resection of Gastrointestinal Tumors Originating from the Muscularis Propria: Analysis of Efficacy and Facility.
- Endoscopic submucosal dissection for silent gastric Dieulafoy lesions mimicking gastrointestinal stromal tumors: Report of 7 cases-a case report series.
- [Prognostic analysis of gastrointestinal stromal tumors complicated with gastrointestinal bleeding].
Cancer
Neuroblastoma
神经母细胞瘤Led no English-language PubMed papers on neuroblastoma in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
10 hospitals in Tianjin for neuroblastoma321 hospitals in China for neuroblastoma
No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)1
Blood disorders
Multiple myeloma
多发性骨髓瘤Led 27 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 1.6%.
5 hospitals in Tianjin for multiple myeloma175 hospitals in China for multiple myeloma
Open trials with this hospital 5
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingThe Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2024-11
- Registry
- NCT06911710
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University General HospitalTianjin
- RecruitingA Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Started
- 2024-07
- Registry
- NCT06083207
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Nanjing, Nanning, Shanghai, Suzhou, Tianjin, Wuhan, Xi'an, Xuzhou
- RecruitingLong-term Follow-up Registry Study of Equecabtagene Autoleucel Injection
- Phase
- Not given
- Started
- 2024-12
- Registry
- NCT07028970
Age not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Tianjin, Wuhan, Zhengzhou
- RecruitingMecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
- Phase
- Phase 2
- Started
- 2022-04
- Registry
- NCT05294055
Age 18 years to 65 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 6 listed hospitals as study sitesBeijing, Hefei, Jinan, Tianjin, Zhengzhou
- RecruitingA Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Started
- 2021-09
- Registry
- NCT04973605
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Chongqing, Fuzhou, Hangzhou, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xiamen, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led27
- Osteoblasts inhibit NK cell killing function via RANK/RANKL in multiple myeloma.
- Combining PIM-2 and PARP1 Inhibitors Induces MICA Expression on Multiple Myeloma Cells to Activate NK Cells through NKG2D Binding.
- Targets Selection for Precision Therapy of Relapsed/Refractory Multiple Myeloma: the Latest Advancements.
- Kaempferol induces mitophagy and disrupts iron metabolism via SFXN2 leading to apoptosis in multiple myeloma cells.
- Enhancing antitumor immunity via ROS-ERS and pyroptosis-induced immunogenic cell death in multiple myeloma.
- T-lymphocytes suppression by CD14+ monocytes with high expression of ULK2 in patients with multiple myeloma.
- Complement C3a promotes the formation of osteoclasts by inhibiting Sirt1 to activate the PI3K/PDK1/SGK3 pathway in patients with multiple myeloma.
- Antitumor effect of BC12-3 on multiple myeloma via proteasome inhibition.
- A case of acute myeloid leukemia and multiple myeloma is observed to occur simultaneously.
- Targeting NKG2D/NKG2DL axis in multiple myeloma therapy.
- Immune profiles to predict bortezomib-based treatment response for multiple myeloma patients.
- BSA-AIE Nanoparticles with Boosted ROS Generation for Immunogenic Cell Death Immunotherapy of Multiple Myeloma.
- Gene therapy with B-cell maturation antigen/CD3 bispecific antibody encoding plasmid DNA for treating multiple myeloma.
- An overview of pim kinase as a target in multiple myeloma.
- Bone marrow-derived mesenchymal stem cells inhibit NK cell function via Tim-3/galectin-9 in multiple myeloma patients.
- Therapeutic strategies to enhance immune response induced by multiple myeloma cells.
- Cellular immunity in the era of modern multiple myeloma therapy.
- Study on the Effect of EZH2 Inhibitor Combined with TIGIT Monoclonal Antibody against Multiple Myeloma Cells.
- Tumor-associated macrophages regulate the function of cytotoxic T lymphocyte through PD-1/PD-L1 pathway in multiple myeloma.
- CD155/TIGIT signalling plays a vital role in the regulation of bone marrow mesenchymal stem cell-induced natural killer-cell exhaustion in multiple myeloma.
- Malignant plasmacytes in bone marrow detected by flow cytometry as a predictor for the risk stratification system of multiple myeloma.
- Roles of LINC01473 and CD74 in osteoblasts in multiple myeloma bone disease.
- Effect of clinical application of anti-CD38 and anti-CD47 monoclonal antibodies on blood group detection and transfusion therapy and treatment.
- Bone marrow-derived mesenchymal stem cells inhibit CD8+ T cell immune responses via PD-1/PD-L1 pathway in multiple myeloma.
- Predictive Role of Immune Profiling for Survival of Multiple Myeloma Patients.
- Review: Effects of anti-CD38 monoclonal antibodies on red blood cell transfusion and interventions.
- lncRNA MSTRG.29039.1 Promotes Proliferation by Sponging hsa-miR-12119 via JAK2/STAT3 Pathway in Multiple Myeloma.
All its trials on ClinicalTrials.gov, any status16
- The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors
- Long-term Follow-up Registry Study of Equecabtagene Autoleucel Injection
- A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
- Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
- A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
- A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
- A Study of NINLARO® in Chinese Adults With Multiple Myeloma
- A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
- A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
- A Study of Ninlaro in Real World Clinical Practice in China
- Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)
- TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
- TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
- Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma
- A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma
Blood disorders
B-cell acute lymphoblastic leukaemia
B 细胞急性淋巴细胞白血病3 hospitals in Tianjin for B-cell acute lymphoblastic leukaemia88 hospitals in China for B-cell acute lymphoblastic leukaemia
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingThe Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2024-11
- Registry
- NCT06911710
Age 18 years to Not stated (registered criteria)
Led by Tianjin Medical University General HospitalTianjin
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
Blood disorders
Aplastic anaemia
再生障碍性贫血Led 23 of the 412 English-language PubMed papers on aplastic anaemia with an author in mainland China, 2021–2025: 5.6%.
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Tianjin for aplastic anaemia63 hospitals in China for aplastic anaemia
No open trial on aplastic anaemia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led23
- From severe aplastic anemia with TERT variant to Wilson disease - associations or not.
- Multi-omics analysis links NFKB1 activation to poor immunosuppressive therapy response in acquired aplastic anemia.
- Role of Macrophage TLR4 Expression in the Immunopathogenesis of Severe Aplastic Anemia.
- Dioscin alleviates aplastic anemia through regulatory T cells promotion.
- HERVs may perform as the initial trigger for acquired aplastic anemia.
- Molecular mechanisms underlying the role of HLA-DQ in systemic immune activation in severe aplastic anemia.
- Partial SAA patients benefit from delayed response of IST.
- The effectiveness of a novel treatment of TIM-3(-) NK cells infusion in murine models of immune-mediated bone marrow failure.
- Traditional Chinese medicine for treating aplastic anemia.
- Single-cell transcriptomic analysis of PB and BM NK cells from severe aplastic anaemia patients.
- New Trends in Nontransplant Therapy for Acquired Aplastic Anemia.
- Abnormal Proteomics Profile of Plasma Reveals the Immunological Pathogenesis of Severe Aplastic Anemia.
- Dioscin Regulating Bone Marrow Apoptosis in Aplastic Anemia.
- A mouse model of irradiation and spleen-thymus lymphocyte infusion induced aplastic anemia.
- Cofilin-1 participates in the hyperfunction of myeloid dendritic cells in patients with severe aplastic anaemia.
- Bone marrow free immune checkpoints as a potential biomarker for differential diagnosis of acquired bone marrow failures.
- Identification of potential pathogenic genes for severe aplastic anemia by whole-exome sequencing.
- Abnormal expression of histone acetylases in CD8+ T cells of patients with severe aplastic anemia.
- Expression and function of SLAMF6 in CD8+ T lymphocytes of patients with severe aplastic anemia.
- Clinical study on empirical and diagnostic-driven (pre-emptive) therapy of voriconazole in severe aplastic anaemia patients with invasive fungal disease after intensive immunosuppressive therapy.
- Upregulated Expression of Profilin1 on Dendritic Cells in Patients With Severe Aplastic Anemia.
- Myeloid dendritic cells in severe aplastic anemia patients exhibit stronger phagocytosis.
- Relationship between immune status after ATG treatment and PNH clone evolution in patients with severe aplastic anemia.
Chinese-language papers (not in the count)11
- [Glucose-regulated protein 78 regulates endoplasmic reticulum stress in the pathogenesis of aplastic anemia].
- [Immune related pancytopenia: a new type of bone marrow failure].
- [Research progress on the pathogenesis of acquired aplastic anemia].
- [How to think about the clinical classifications of acquired aplastic anemia].
- [Interpretiation of guidelines for the diagnosis and management of aplastic anemia in China (2022)].
- [The expression and correlation analysis of TOX and inhibitory receptors on peripheral blood CD8+T cells in patients with aplastic anemia].
- [Abnormal expression of CXCR5+CD8+ T cells and CXCL13 in severe aplastic anemia patients and their correlation with hematological parameters].
- [Exclusive diagnosis of aplastic anemia].
- [Research Progress on Pathogenesis of Congenital Pure Red Cell Aplasia---Review].
- [Study on the loss of HLA-A allele expression in patients with aplastic anemia].
- [Immune regulatory effect of tacrolimus in patients with severe aplastic anemia and in murine model].
All its trials on ClinicalTrials.gov, any status1
Blood disorders
Thrombotic thrombocytopenic purpura
血栓性血小板减少性紫癜Led 1 of the 64 English-language PubMed papers on thrombotic thrombocytopenic purpura with an author in mainland China, 2021–2025: 1.6%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Tianjin for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura
No open trial on thrombotic thrombocytopenic purpura lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led1
Other diseases
Neuromyelitis optica spectrum disorder
视神经脊髓炎谱系疾病Led 22 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 4.5%.
2 hospitals in Tianjin for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder
Open trials with this hospital 4
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingModified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder
- Phase
- Phase 3
- Started
- 2026-01
- Registry
- NCT07420296
Age 18 years to 80 years (registered criteria)
Led by Tianjin Medical University General HospitalTianjin
- RecruitingSafety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases
- Phase
- Phase 1/Phase 2
- Started
- 2025-04
- Registry
- NCT07022197
Age 18 years to 60 years (registered criteria)
Led by Tianjin Medical University General HospitalTianjin
- RecruitingA Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
- Phase
- Phase 2/Phase 3
- Started
- 2024-07
- Registry
- NCT06413654
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiamen, Zhengzhou
- RecruitingClinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)
- Phase
- Early phase 1
- Started
- 2022-04
- Registry
- NCT05145361
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Taiyuan, Tianjin, Xi'an
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led22
- A real-world comparative study on the efficacy and safety of tocilizumab and rituximab in patients with neuromyelitis optica spectrum disease and myelin oligodendrocyte glycoprotein antibody-associated disease.
- Type I Interferon Signaling Augments Autoimmunity in Neuromyelitis Optica Spectrum Disorder.
- Changes in T lymphocyte subsets in patients with acute neuromyelitis optica spectrum disorder.
- Astrocytes and microglia in multiple sclerosis and neuromyelitis optica.
- Ofatumumab treatment in patients with neuromyelitis optica spectrum disorder: a retrospective multicenter cohort study.
- Effectiveness and safety of glucocorticoids bridging rituximab in neuromyelitis spectrum disorder.
- Elevated levels of cerebrospinal fluid CHIT1 correlate with disease activity in neuromyelitis optica spectrum disorder.
- Early versus escalation treatment of tocilizumab in neuromyelitis optica spectrum disorder: a retrospective study.
- 4-Octyl itaconate inhibits inflammation via the NLRP3 pathway in neuromyelitis optica spectrum disorders.
- Susceptibility-weighted image features in AQP4-negative-NMOSD versus MS.
- Targeting B cells in neuromyelitis optica spectrum disorder.
- Serum neurofilament light chain predicts spinal cord atrophy in neuromyelitis optica spectrum disorder.
- Rituximab induces a transient fluctuation of peripheral and follicular helper T cells in neuromyelitis optica spectrum disorder.
- Bruton's tyrosine kinase-bearing B cells and microglia in neuromyelitis optica spectrum disorder.
- A real-world study of interleukin-6 receptor blockade in patients with neuromyelitis optica spectrum disorder.
- Personalized estimates of morphometric similarity in multiple sclerosis and neuromyelitis optica spectrum disorders.
- The prevalence of anti-neurofascin-155 antibodies in patients with neuromyelitis optica spectrum disorders.
- Group 2 innate lymphoid cells suppress the pathology of neuromyelitis optica spectrum disorder.
- Early Initiation of Tocilizumab Treatment Against Moderate-to-Severe Myelitis in Neuromyelitis Optica Spectrum Disorder.
- Effects of Tocilizumab Therapy on Circulating B Cells and T Helper Cells in Patients With Neuromyelitis Optica Spectrum Disorder.
- Elevated cerebrospinal fluid β2-microglobulin levels in patients with neuromyelitis optica spectrum disorders.
- Cerebrospinal fluid lactate level in aquaporin-4 antibody positive neuromyelitis optica spectrum disorders: a hint on differential diagnosis and possible immunopathogenesis.
All its trials on ClinicalTrials.gov, any status15
- Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder
- Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases
- Eculizumab For the Acute Attack of Neuromyelitis Optica Spectrum Disorder
- Efficacy and Safety of Ruxolitinib in Neuromyelitis Optica Spectrum Disorders
- Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum Disorders
- Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders
- Effects of Ofatumumab Treatment on Immune Cells and Meningeal Lymphatic Drainage in Patients With Demyelinating Diseases
- Efficacy and Safety of Belimumab in Neuromyelitis Optica Spectrum Disorders
- Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders
- Efficacy and Safety of Bortezomib as add-on Treatment in Relapsing Neuromyelitis Optica Spectrum Disorder
- Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders
- A Longitudinal Study of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active NMOSD
- A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
- Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)
- A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders
More papers found outside PubMed (not counted)2
Other diseases
IgG4-related disease
IgG4相关性疾病Led 3 of the 246 English-language PubMed papers on IgG4-related disease with an author in mainland China, 2021–2025: 1.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Tianjin for IgG4-related disease46 hospitals in China for IgG4-related disease
No open trial on IgG4-related disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led3
- Single-cell transcriptome analysis profiles cellular and molecular alterations in submandibular gland and blood in IgG4-related disease.
- Clinical Characteristics and Potential Mechanisms in Patients with Abnormal Liver Function Indices and Elevated Serum IgG4.
- IgG4-Related Disease with Ascites: Report of a Case Simulating Primary Peritoneal Papillary Serous Carcinoma.
Other diseases
Myasthenia gravis
重症肌无力Led 21 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 4.2%.
2 hospitals in Tianjin for myasthenia gravis89 hospitals in China for myasthenia gravis
Open trials with this hospital 5
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingSafety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases
- Phase
- Phase 1/Phase 2
- Started
- 2025-04
- Registry
- NCT07022197
Age 18 years to 60 years (registered criteria)
Led by Tianjin Medical University General HospitalTianjin
- RecruitingClinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)
- Phase
- Phase 1
- Started
- 2025-09
- Registry
- NCT07215650
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesChangchun, Chengdu, Fuzhou, Guangzhou, Guiyang, Shanghai, Taiyuan, Tianjin, Zhengzhou
- RecruitingMyasthenia Gravis Registry in China
- Phase
- Not given
- Started
- 2024-02
- Registry
- NCT06241521
Age not stated (registered criteria)
Led by Huashan Hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Nanchang, Shanghai, Suzhou, Tianjin, Xi'an, Xuzhou, Zhengzhou
- RecruitingEfficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis
- Phase
- Phase 2
- Started
- 2022-07
- Registry
- NCT05067348
Age 18 years to 80 years (registered criteria)
Led by Tangdu Hospital; 5 listed hospitals as study sitesBeijing, Changsha, Chengdu, Shanghai, Tianjin, Xi'an
- RecruitingA Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
- Phase
- Phase 3
- Started
- 2021-07
- Registry
- NCT04951622
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Shanghai, Tianjin, Xi'an
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led21
- The prognosis of MG patients with different thymic pathology: a multicenter retrospective cohort study.
- Single-cell atlas reveals heterogeneous response to FcRn blockade in anti-AChR antibody-positive generalised myasthenia gravis.
- Treatment strategy for myasthenia gravis with GAD65-IgG associated neurological disorders: A case report.
- Outcomes in Relation to the Age at Onset in Patients With Myasthenia Gravis.
- The role of regulatory B cell/T follicular helper cell balance in thymoma and thymoma-associated myasthenia gravis.
- Responsiveness to Tocilizumab in Anti-Acetylcholine Receptor-Positive Generalized Myasthenia Gravis.
- Clinical features of COVID-19 infection in patients with myasthenia gravis: a real-world retrospective study.
- Serum amyloid A facilitates expansion of CD4+ T cell and CD19+ B cell subsets implicated in the severity of myasthenia gravis patients.
- Distribution of multi-level B cell subsets in thymoma and thymoma-associated myasthenia gravis.
- Thymectomy in thymomatous generalized myasthenia gravis: An analysis of the prognosis and risk factors.
- TLR4-MyD88-NF-κB signaling imbalances Th17 and Treg cells in thymoma with myasthenia gravis.
- Expression of TRAF6 in peripheral blood B cells of patients with myasthenia gravis.
- Roles of IL-35-producing T and B cells in anti-acetylcholine receptor antibody-positive myasthenia gravis.
- Serum irisin levels in patients with myasthenia gravis.
- Thymectomy in ocular myasthenia gravis-prognosis and risk factors analysis.
- Two types of immune infiltrating cells and six hub genes can predict the occurrence of myasthenia gravis in patients with thymoma.
- Efficacy and safety of different dosages of rituximab for refractory generalized AChR myasthenia gravis: A meta-analysis.
- Increased serum IL-27 concentrations and IL-27-producing cells in MG patients with positive AChR-Ab.
- Low-dose rituximab treatment for new-onset generalized myasthenia gravis.
- Imbalance of Th17 and Tregs in thymoma may be a pathological mechanism of myasthenia gravis.
- Effects of thymectomy on late-onset non-thymomatous myasthenia gravis: systematic review and meta-analysis.
All its trials on ClinicalTrials.gov, any status9
- Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases
- The Specificity, Sensitivity and Clinical Correlation of CBA, RIPA and ELISA in Detecting AChR and MuSK IgG of Myasthenia Gravis
- Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)
- Myasthenia Gravis Registry in China
- Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis
- A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
- Open-Label Extension of Tocilizumab in Subjects With Generalized Myasthenia Gravis
- A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis
- A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis
Other diseases
Moyamoya disease
烟雾病Led 2 of the 356 English-language PubMed papers on moyamoya disease with an author in mainland China, 2021–2025: 0.6%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Tianjin for moyamoya disease47 hospitals in China for moyamoya disease
No open trial on moyamoya disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Papers it led2
More papers found outside PubMed (not counted)1
Other diseases
Takayasu arteritis
大动脉炎Led no English-language PubMed papers on Takayasu arteritis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Tianjin for Takayasu arteritis100 hospitals in China for Takayasu arteritis
No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
Other diseases
Idiopathic pulmonary fibrosis
特发性肺纤维化Led 7 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.7%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
10 hospitals in Tianjin for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingStudy Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- Phase
- Phase 3
- Started
- 2026-09
- Registry
- NCT07687459
Age 40 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Hohhot, Jinan, Kunming, Nanchang, Nanjing, Nanning, Nanyang, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yichang, Yuncheng, Zhengzhou
- RecruitingA Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis
- Phase
- Phase 2
- Started
- 2025-11
- Registry
- NCT07121413
Age 40 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesChengdu, Guangzhou, Hangzhou, Hohhot, Nanchang, Nanjing, Shanghai, Tianjin, Xuzhou, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led7
- Roflumilast mitigates idiopathic pulmonary fibrosis via inhibition of iron accumulation and ferroptosis.
- The histone demethylase KDM6B links obstructive sleep apnea to idiopathic pulmonary fibrosis.
- Identification and validation of CDC20 and ITCH as ubiquitination related biomarker in idiopathic pulmonary fibrosis.
- Add-On Dextromethorphan Improves the Effects of Pirfenidone in Bleomycin-Treated Mice and Patients With Pulmonary Fibrosis.
- Potential biomarkers for diagnosis and disease evaluation of idiopathic pulmonary fibrosis.
- Identification of autophagy-related genes in idiopathic pulmonary fibrosis using bioinformatics methods.
- Role of various imbalances centered on alveolar epithelial cell/fibroblast apoptosis imbalance in the pathogenesis of idiopathic pulmonary fibrosis.
All its trials on ClinicalTrials.gov, any status13
- Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis
- Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary Fibrosis
- A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
- A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis
- A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
- Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis
- Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)
- A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
- A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis
- A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis
- Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
- Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Other diseases
Amyotrophic lateral sclerosis
肌萎缩侧索硬化症Led 1 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
5 hospitals in Tianjin for amyotrophic lateral sclerosis182 hospitals in China for amyotrophic lateral sclerosis
No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led1
Other diseases
Spinal muscular atrophy
脊髓性肌萎缩症Led 1 of the 55 English-language PubMed papers on spinal muscular atrophy with an author in mainland China, 2021–2025: 1.8%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Tianjin for spinal muscular atrophy49 hospitals in China for spinal muscular atrophy
No open trial on spinal muscular atrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Duchenne muscular dystrophy
杜氏肌营养不良Led 2 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 0.9%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
4 hospitals in Tianjin for Duchenne muscular dystrophy111 hospitals in China for Duchenne muscular dystrophy
No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
Other diseases
Alport syndrome
Alport 综合征Led 1 of the 58 English-language PubMed papers on Alport syndrome with an author in mainland China, 2021–2025: 1.7%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Tianjin for Alport syndrome60 hospitals in China for Alport syndrome
No open trial on Alport syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
IgA nephropathy
IgA 肾病Led 10 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 1.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
5 hospitals in Tianjin for IgA nephropathy300 hospitals in China for IgA nephropathy
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingEvaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases
- Phase
- Phase 2
- Started
- 2026-05
- Registry
- NCT07614477
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Tianjin
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led10
- The neutrophil-to-monocyte ratio: a superior inflammatory marker predicting poor prognosis in IgA nephropathy.
- Increased soluble CD16b derived from activated neutrophils in plasma is associated with the pathogenesis and progression of IgA nephropathy.
- Clinical and pathological findings of IgA nephropathy following SARS-CoV-2 infection.
- Prognosis of IgA Nephropathy with Stages 3b-5 CKD.
- The effect of fibrinoid necrosis on the clinical features and outcomes of primary IgA nephropathy.
- Deciphering prognostic value of CD22 and its contribution to suppression of proinflammatory cytokines production in patients with IgA nephropathy.
- Effect of hematuria on the kidney disease progression in IgA nephropathy patients with mild proteinuria and well-preserved renal function.
- Circulating platelets supply ST6Gal-1 in patients with IgA nephropathy.
- The difference between patients with nephrotic syndrome and nephrotic-range proteinuria in IgA nephropathy: a propensity score matched cohort study.
- Sialylation of IgG inhibits the formation of galactose-deficient IgA1-containing immune complexes and protects mesangial cells from injury in IgA nephropathy.
Earlier papers (2016–2020)9
- A case presentation of an IgA nephropathy patient with Vogt-Koyanagi-Harada syndrome.
- C1GALT1 expression is associated with galactosylation of IgA1 in peripheral B lymphocyte in immunoglobulin a nephropathy.
- ST6Gal1 is up-regulated and associated with aberrant IgA1 glycosylation in IgA nephropathy: An integrated analysis of the transcriptome.
- ELL2 Is Downregulated and Associated with Galactose-Deficient IgA1 in IgA Nephropathy.
- Comprehensive analysis of aberrantly expressed profiles of mRNA and its relationship with serum galactose-deficient IgA1 level in IgA nephropathy.
- Clinical Significance of Galactose-Deficient IgA1 by KM55 in Patients with IgA Nephropathy.
- Changes E3 ubiquitin protein ligase 1 gene mRNA expression correlated with IgA1 glycosylation in patients with IgA nephropathy.
- Corticosteroid for IgA Nephropathy: Are They Really Therapeutic?
- A Systematic Review and Meta-Analysis of Kidney and Pregnancy Outcomes in IgA Nephropathy.
All its trials on ClinicalTrials.gov, any status2
Other diseases
Osteogenesis imperfecta
成骨不全症Led 4 of the 99 English-language PubMed papers on osteogenesis imperfecta with an author in mainland China, 2021–2025: 4.0%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Tianjin for osteogenesis imperfecta58 hospitals in China for osteogenesis imperfecta
No open trial on osteogenesis imperfecta lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led4
- Surgical treatment of osteogenesis imperfecta: a summary of the incidence of femoral implant-related complications in children with Sillence type I, III and IV.
- Height prediction of individuals with osteogenesis imperfecta by machine learning.
- Which is the best femoral implant in children with osteogenesis imperfecta? a retrospective cohort study of 783 procedures.
- The patient-related factors in revision procedures on tibia of patients with osteogenesis imperfecta treated with the Peter-Williams nail.
Other diseases
Primary biliary cholangitis
原发性胆汁性胆管炎Led 7 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 2.3%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
4 hospitals in Tianjin for primary biliary cholangitis153 hospitals in China for primary biliary cholangitis
Open trials with this hospital 3
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
- Phase
- Phase 3
- Started
- 2025-12
- Registry
- NCT07282353
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBaoji, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Hangzhou, Harbin, Hefei, Linyi, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shiyan, Taizhou, Tianjin, Xi'an, Xiamen, Zhanjiang, Zhengzhou
- RecruitingFenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis
- Phase
- Phase 2/Phase 3
- Started
- 2023-02
- Registry
- NCT05749822
Age 18 years to 75 years (registered criteria)
Led by Xijing Hospital; 11 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Kunming, Nanjing, Shenyang, Tianjin, Xi'an, Yan'an, Zhengzhou
- RecruitingFenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis
- Phase
- Phase 3
- Started
- 2023-02
- Registry
- NCT05751967
Age 18 years to 75 years (registered criteria)
Led by Xijing Hospital; 6 listed hospitals as study sitesChengdu, Guangzhou, Lanzhou, Nanjing, Shenyang, Tianjin, Xi'an
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Papers it led7
- The Depletion of Plasma Cells but Not CD20+B Cells Alleviates Primary Biliary Cholangitis.
- Characterisation and Clinical Relevance of Tertiary Lymphoid Structures in Primary Biliary Cholangitis.
- Lactococcus garvieae aggravates cholestatic liver disease by increasing intestinal permeability and enhancing bile acid reabsorption.
- Associations between sleep disorders and clinical outcomes of patients with primary biliary cholangitis.
- Depressive symptom as a risk factor for cirrhosis in patients with primary biliary cholangitis: Analysis based on Lasso-logistic regression and decision tree models.
- Anti-gp210-positive primary biliary cholangitis: The dilemma of clinical treatment and emerging mechanisms.
- Novel HLA-DRB1 alleles contribute risk for disease susceptibility in primary biliary cholangitis.
Chinese-language papers (not in the count)2
Earlier papers (2016–2020)2
All its trials on ClinicalTrials.gov, any status3
Other diseases
Primary sclerosing cholangitis
原发性硬化性胆管炎Led 1 of the 100 English-language PubMed papers on primary sclerosing cholangitis with an author in mainland China, 2021–2025: 1.0%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
2 hospitals in Tianjin for primary sclerosing cholangitis89 hospitals in China for primary sclerosing cholangitis
Open trials with this hospital 1
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingA Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
- Phase
- Phase 3
- Started
- 2026-05
- Registry
- NCT07387549
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changchun, Guangzhou, Jinan, Nanchang, Shanghai, Tianjin, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Chinese-language papers (not in the count)1
Earlier papers (2016–2020)1
All its trials on ClinicalTrials.gov, any status1
Other diseases
Hirschsprung disease
先天性巨结肠Led no English-language PubMed papers on Hirschsprung disease in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Tianjin for Hirschsprung disease76 hospitals in China for Hirschsprung disease
No open trial on Hirschsprung disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Other diseases
Familial adenomatous polyposis
家族性腺瘤性息肉病Led no English-language PubMed papers on familial adenomatous polyposis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Tianjin for familial adenomatous polyposis74 hospitals in China for familial adenomatous polyposis
No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Earlier papers (2016–2020)3
- Adenomatous Polyposis Coli Gene Mutations in 22 Chinese Pedigrees with Familial Adenomatous Polyposis.
- Targeted next-generation sequencing approach for molecular genetic diagnosis of hereditary colorectal cancer: Identification of a novel single nucleotide germline insertion in adenomatous polyposis coli gene causes familial adenomatous poly
- A novel pathogenic splice acceptor site germline mutation in intron 14 of the APC gene in a Chinese family with familial adenomatous polyposis.
Other diseases
Leber hereditary optic neuropathy
Leber 遗传性视神经病变Led 3 of the 52 English-language PubMed papers on Leber hereditary optic neuropathy with an author in mainland China, 2021–2025: 5.8%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Tianjin for Leber hereditary optic neuropathy30 hospitals in China for Leber hereditary optic neuropathy
No open trial on Leber hereditary optic neuropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Papers it led3
Earlier papers (2016–2020)1
Getting in touch
Name card to show staff or a driver
天津医科大学总医院
Tianjin Medical University General Hospital
天津
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.
Identifiers and other names
ROR Wikidata
General Hospital of Tianjin Medical University; Tianjin General Hospital; Tianjin Medical University General Hospital Airport Site; Binhai Hospital of Tianjin Medical University General Hospital; Tianjin Medical University General HospitalTianjinP.R. China; Tianjin Medical University General Hospital Airport Hospital; Tianjin Medical University General hospital; Tianjin Medical University General Hospital Hospital